Mind-body Medicine for Patients With Malignant Hematological Diseases
Launched by UNIVERSITÄT DUISBURG-ESSEN · Nov 7, 2018
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how a mind-body group program can help patients with certain blood cancers, known as malignant hematological diseases, manage feelings of fatigue. The study is currently recruiting participants aged 65 to 74 who are in complete remission after their initial treatment, such as chemotherapy or radiation. To join, patients need to be able to attend at least 8 out of 11 group sessions and should not be receiving any other treatments or participating in other studies that involve behavioral therapies during the trial.
Participants in this trial can expect to engage in a supportive group environment where they can learn techniques to help reduce fatigue and improve their overall well-being. It's an opportunity to explore how connecting the mind and body might enhance their recovery experience. If you're interested and meet the eligibility criteria, this could be a chance to contribute to research aimed at improving the quality of life for patients with blood cancers.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with malignant hematological diseases in complete remission after primary chemotherapy and/or radiation
- • Physical and mental ability to attent 8 of 11 group units
- Exclusion Criteria:
- • Chemotherapy, radiation, or rehabilitation programm during the study period
- • Pregnancy
- • Participation in other studies with behavioral interventions during the study period
About Universität Duisburg Essen
The Universität Duisburg-Essen is a prominent academic institution in Germany, renowned for its commitment to research and innovation in various fields, including medicine and health sciences. As a clinical trial sponsor, the university leverages its interdisciplinary expertise and state-of-the-art facilities to advance clinical research initiatives. With a focus on improving patient outcomes, the university actively collaborates with healthcare professionals, industry partners, and regulatory bodies to conduct rigorous clinical trials that adhere to the highest ethical and scientific standards. Through its dedication to enhancing clinical knowledge and fostering new therapeutic approaches, Universität Duisburg-Essen plays a pivotal role in the evolution of modern healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stuttgart, , Germany
Patients applied
Trial Officials
Gustav Dobos, Prof. MD
Study Director
Center for Integrative Medicine and Health, University Hospital Essen, University of Duisburg-Essen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials